AstraZeneca has begun a phase-one trial of an antibody treatment to “prevent or treat” coronavirus, the British pharma giant confirmed in a London stock exchange statement on 25 August.

The trial will include up to 48 healthy participants in the UK, aged between 18 and 55 years.